Sarcoma  >>  izuralimab (XmAb23104) 
Welcome,         Profile    Billing    Logout  

2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
izuralimab (XmAb23104) / Xencor
NCT05879185: A Study of XmAb23104 in People With Sarcoma

Active, not recruiting
2
6
US
XmAb23104
Memorial Sloan Kettering Cancer Center, Xencor, Inc.
Sarcoma
04/25
04/25
DUET-3, NCT03752398: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Calendar Jan 2024 - Dec 2024: From DUET-3 trial for advanced solid tumors
Active, not recruiting
1
300
US
XmAb®23104, Yervoy® (ipilimumab)
Xencor, Inc., ICON plc
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
12/24
09/25

Download Options